Category Archives: National Right to Life

WASHINGTON — National Right to Life is pleased to endorse Michelle Fischbach (R) for election to the U.S. House of Representatives to represent the 7th Congressional District of Minnesota. Michelle Fischbach is a proven and accomplished pro-life leader with a 100% lifetime pro-life voting record in the Minnesota State Senate. During her time in the […]

WASHINGTON—Today, the National Right to Life Committee (NRLC) praised a motion introduced by House Republicans to include unborn children in the “vulnerable populations” the Environmental Protection Agency (EPA) should consider when it works on the development of drinking water standards. The “Motion to Recommit” would have amended the Safe Drinking Water Act to add “any […]

The National Right to Life Committee (NRLC) praised the Trump Administration for filing an amicus brief with the U.S. Supreme Court in support of Louisiana’s Act 620, known as the “Unsafe Abortion Protection Act.” The act, which passed by overwhelming margins in 2014, requires abortionists to have admitting privileges with a local hospital. The U.S. Supreme Court […]

The National Right to Life Committee (NRLC) and Louisiana Right to Life (LRTL) have filed an amicus brief with the U.S. Supreme Court supporting Louisiana’s Act 620 “Unsafe Abortion Protection Act” which requires abortion doctors to have admitting privileges with a local hospital. Act 620 was passed in 2014 in response to the extensive health and safety […]

The following statement can be attributed to Carol Tobias, president of National Right to Life: “With this final rule, the Trump Administration is enforcing rules that were implemented under the Obama Administration but never enforced. This rule will prevent taxpayer dollars from being used to pay for abortion coverage in Obamacare health insurance policies. We […]

The “Lower Drug Costs Now Act of 2019” (H.R. 3) passed by the House of Representatives—on nearly a party-line vote of 230-192—would endanger patients by leading to a loss of anywhere between 100 to 400 new drugs in the U.S. over the next decade and reduce the average life expectancy of Americans by fourth months, […]

The “Lower Drug Costs Now Act of 2019” (H.R. 3) passed by the House of Representatives—on nearly a party-line vote of 230-192—would endanger patients by leading to a loss of anywhere between 100 to 400 new drugs in the U.S. over the next decade and reduce the average life expectancy of Americans by fourth months, […]

To view or download a PDF version of this letter, click here.   RE: H.R. 3, the so-called “Lower Drug Costs Now Act of 2019” Dear Member of Congress: This week, the House is expected to vote on H.R. 3, the so-called “Lower Drug Costs Now Act of 2019.” The National Right to Life Committee […]

A new analysis of the Lower Drug Costs Now Act of 2019 (H.R. 3) by the Council of Economic Advisers (CEA) estimates that, if passed, the legislation could lead to a loss of as many as 100 new drugs in the U.S. over the next decade. “Congress should not set up price controls that will […]